Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small molecules to improve the lives of patients with genetically defined rare diseases where there is a high unmet medical need. The company's main product candidate, pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is currently in clinical development for treating sickle cell disease (SCD). Fulcrum Therapeutics completed dosing in the PIONEER trial, a Phase 1b clinical trial that evaluated pociredir in adults with SCD. This trial included 12 mg and 20 mg once-daily dose cohorts and treated subjects over a 12-week period. Clinical data from this trial showed clinically relevant HbF induction, including progression toward pan-cellular distribution, and improvements in markers of hemolysis and anemia. The company is currently activating sites for an open-label extension trial to assess longer-term safety and pharmacodynamic (PD) durability in patients who completed the PIONEER trial. Details for the next trial are planned for the second quarter of 2026, after receiving meeting minutes from an End-of-Phase meeting with the FDA. Subject to FDA feedback, a potential registration-enabling trial is planned for initiation in the second half of 2026. Fulcrum Therapeutics also uses a discovery approach to identify and validate cellular drug targets that can modulate gene expression to address the root causes of genetically defined rare diseases. This approach led to the identification of pociredir for SCD and other drug candidates. The company is exploring additional mechanisms that could complement pociredir's action to induce HbF for SCD treatment. Preclinical data for FTX-6274, an oral EED inhibitor candidate, was presented at the European Society for Medical Oncology (ESMO) Congress 2025, showing tumor growth inhibition in preclinical prostate cancer models. Based on results from IND-enabling studies, the company has decided not to advance its program for bone marrow failure syndromes into clinical development, instead focusing resources on pociredir and its core benign hematology programs.